Clinical Trial

ABY-029 Head & Neck Trial

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purposes of the research trial are to study the safety of ABY-029 and to understand how much of the drug is needed to reach head and neck squamous cell carcinomas (HNSCC) so it can be visualized best by surgeons. Investigators will do this by comparing two groups of participants that receive different, very small amounts of ABY-029. Investigators will use an imaging system during surgery to record the amount of ABY-029 in the participant's tumor and in the surrounding tissue.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-08.
Trial Details
NCT Number NCT07279116
Lead Sponsor Dartmouth-Hitchcock Medical Center
Collaborators: Dartmouth College, National Cancer Institute (NCI)
Conditions Head and Neck Squamous Cell Carcinoma
Enrollment 24 participants
Start Date 2026-06-30
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-07